Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam Study

Archives of Internal Medicine

Volumn 159, Issue 1, 1999, Pages 38-44

  Bots, Michiel L ^a   Launer, Lenore J ^b   Lindemans, Jan ^c   Hoes, Arno W ^c   Hofman, Albert ^d   Witteman, Jacqueline C M ^d   Koudstaal, Peter J ^c   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ACUTE HEART INFARCTION; AGED; AGING; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MYOCARDIAL INFARCTION; NETHERLANDS; ODDS RATIO; RISK; RISK FACTORS;

EID: 0033545179     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.1.38     Document Type: Article

References (37)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995; 274:1049-1057.
2. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis. 1978;31: 201-306.
3. Psaty BM, Koepsel TD, Manolio TA, et al. Risk ratios and risk differences in estimating the effect of risk factors for cardiovascular disease in the elderly. J Clin Epidemiol. 1990;43:961-970.
4. Stampfer MJ, Malinow MR, Willet WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992; 268:877-881.
5. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willet W, Stampfer MJ. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke. 1994; 25:1924-1930.
6. Nygárd O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995;274: 1526-1533.
7. Hofman A, Grobbee DE, De Jong PTVM, Vandenouweland FAM. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-422.
8. van der Bom JG, Bots ML, de Bruijn AM, Hofman A, Grobbee DE. Measurement of β-thromboglobulin in the elderly: findings from the Rotterdam Study. Fibrinolysis. 1994;8(suppl 2):157-159.
9. Vangent CM, Vandervoort HA, De Bruyn AM, Klein F. Cholesterol determinations: a comparative study of methods with special reference to enzymatic procedures. Clin Chim Acta. 1977;75:243-251.
10. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
11. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991; 465:441-446.
12. Lamberts H, Wood M, Hofmans-Okkes I. The International Classification of Primary Care in the European Community. Oxford, England: Oxford University Press; 1991.
13. Bots ML, Looman SJ, Koudstall PJ, Hofman A, Hoes AW, Grobbee DE. Prevalence of stroke in the general population: the Rotterdam Study. Stroke. 1997; 27:1499-1501.
14. Grobbee DE, Koudstaal PJ, Bots ML, et al. Incidence and risk factors for ischaemic and haemorrhagic stroke in Europe: EUROSTROKE: a collaborative study among research centres in Europe: rationale and design. Neuroepidemiology. 1996;15:291-300.
15. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991; 1:1521-1526.
16. European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
17. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. The effect of blood sample ageing and food consumption on plasma total homocysteine levels. Clin Chem Acta. 1992;207:119-128.
18. Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr. 1994;124:1934-1941.
19. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764-1779.
20. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 1994; 236:603-617.
21. Brattstrom L, Lindgren A, Israelsson B, Anderson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med. 1994;236:633-641.
22. Verhoef P. Homocysteine, B-Vitamins and Cardiovascular Disease: Epidemiologic Evidence [dissertation]. Wageningen, the Netherlands: Wageningen Agricultural University; 1996.
23. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
24. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordre JE. Serum total homocysteine and coronary heart disease, Int J Epidemiol. 1995;24:704-709.
25. Alfthan G, Pekkanen J, Jouhiainan M, et al. Relation of serum homocysteine and lipoprotein(a) to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
26. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: the Rotterdam Study. Intern Med. 1997;242:339-347.
27. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid artery disease. N Engl J Med. 1995; 332:286-291.
28. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond MG. Carotid intimal-medial wall thickening and plasma homocysteine in asymptomatic adults: the Atherosclerosis Risk in Communities study. Circulation. 1993;87:1107-1113.
29. 12 and folate. Am J Epidemiol. 1996;143:845-859.
30. Stamler JS, Osborne JA, Jaraki O, et al. Adverse effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:3008-3018.
31. McDonald L, Bray C, Field C, Love F, Davis B. Homocystinuria, thrombosis and the blood platelet. Lancet. 1964;1:745-746.
32. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
33. Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alteration of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis. 1996;122: 201-216.
34. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med. 1996;19:171-178.
35. Ma J, Stampfer MJ, Hennekens C, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infaction in US physicians. Circulation. 1996;94:2410-2416.
36. 6 supplements in elderly people with normal serum vitamin concentrations. Lancet. 1995;346:85-89.
37. Brattstrom L. Vitamins as homocysteine-lowering agents. J Nutr. 1996;126 (suppl 4):1276S-1280S.